Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Carbohydrate-binding proteins fill in gaps in immune defenses

Our bodies produce a family of proteins that recognize and kill bacteria whose carbohydrate coatings resemble those of our own cells too closely, scientists have discovered.

13 May 2014

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2014.

12 May 2014

Researchers reveal how protein acts as brake against pathological growth of heart muscle

Cardiovascular disease remains the number one cause of death in the Western world, with heart failure representing the fastest-growing subclass over the past decade.

12 May 2014

Experimental antibody temporarily halts progression of neuroblastoma in children

Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.

9 May 2014

ImaginAb announces completion of $21M Series B financing

ImaginAb, Inc., a clinical stage biotechnology company that engineers antibodies into smaller protein formats optimized for in vivo molecular imaging, announced today the completion of a $21M Series B financing of the company, led by Mérieux Développement and syndicated with Novartis Venture Funds, Cycad Group and Nextech Invest.

9 May 2014

3 pioneering cell biologists win 2014 E.B. Wilson Medal from American Society for Cell Biology

If cells were cars, then the three pioneering cell biologists just named winners of the 2014 E.B. Wilson Medal, the highest scientific honor of the American Society for Cell Biology, helped write the essential parts list.

8 May 2014

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Lipids, primarily cholesterol and triglycerides, come from two sources: what is naturally manufactured in the liver and what comes from the intestines through the diet.

From Sanofi 7 May 2014

FDA accepts Merck's MK-3475 BLA for review

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for MK-3475, Merck's investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab.

6 May 2014

Macrogenics, CMC Biologics sign agreement to develop oncology product candidate

CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics' product candidates.

6 May 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

Covagen today announced it has initiated a Phase Ib/IIa study with COVA322, a bispecific TNF/IL-17A inhibitor.

6 May 2014

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).

6 May 2014

Research provides definitive evidence of safety of Tdap immunization during pregnancy

A preliminary study finds that receipt of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in the third trimester of pregnancy did not increase the risk of adverse events for the mother or infant, according to a study in the May 7 issue of JAMA, a theme issue on child health.

5 May 2014

Researchers identify novel proceed to treat brittle bone disease

Researchers at Baylor College of Medicine have identified a new approach to treating brittle bone disease, a congenital disorder that results in fragile bones that break easily.

5 May 2014

Biotech to the rescue

MIT professor Ram Sasisekharan's three biotech companies — Momenta Pharmaceuticals, Cerulean Pharma, and Visterra — share a similar goal.

1 May 2014

Genetic biomarkers of ranibizumab response remain elusive in Koreans with AMD

Researchers have failed to find a significant genotypic effect on ranibizumab treatment response in Korean patients with neovascular age-related macular degeneration.

1 May 2014

Enrichment of highly abundant epigenetic marks from endometrial stromal cells

Chromatrap®, the novel solid-based matrix for chromatin immunoprecipitation (ChIP) assays, available from Porvair Sciences, has been successfully used to isolate high quality chromatin from difficult biopsy material.

From Chromatrap® - Porvair Sciences Ltd 30 Apr 2014

Bristol-Myers Squibb completes acquisition of iPierian

Bristol-Myers Squibb Company and iPierian, Inc. announced today that Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.

29 Apr 2014

Adhesion molecule offers promising therapeutic target for preventing colitis

May Provide Therapeutic Target for Treating Inflammatory Bowel Disease and Preventing Colitis-Associated Colorectal Cancer, According to New Research Published in The American Journal of Pathology

29 Apr 2014

Scientists identify natural human antibodies against virus that causes MERS

Scientists at Dana-Farber Cancer Institute have identified natural human antibodies against the virus that causes Middle East Respiratory Syndrome (MERS), a step toward developing treatments for the newly emerging and often-fatal disease.

29 Apr 2014

Antibody News and Research

Further Reading

Carbohydrate-binding proteins fill in gaps in immune defenses

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Researchers reveal how protein acts as brake against pathological growth of heart muscle

Experimental antibody temporarily halts progression of neuroblastoma in children

ImaginAb announces completion of $21M Series B financing

3 pioneering cell biologists win 2014 E.B. Wilson Medal from American Society for Cell Biology

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

FDA accepts Merck's MK-3475 BLA for review

Macrogenics, CMC Biologics sign agreement to develop oncology product candidate

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Research provides definitive evidence of safety of Tdap immunization during pregnancy

Researchers identify novel proceed to treat brittle bone disease

Biotech to the rescue

Genetic biomarkers of ranibizumab response remain elusive in Koreans with AMD

Enrichment of highly abundant epigenetic marks from endometrial stromal cells

Bristol-Myers Squibb completes acquisition of iPierian

Adhesion molecule offers promising therapeutic target for preventing colitis

Scientists identify natural human antibodies against virus that causes MERS

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo